303 related articles for article (PubMed ID: 32312891)
1. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with
Smyth LM; Tamura K; Oliveira M; Ciruelos EM; Mayer IA; Sablin MP; Biganzoli L; Ambrose HJ; Ashton J; Barnicle A; Cashell DD; Corcoran C; de Bruin EC; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Pass M; Rowlands V; Schiavon G; Banerji U; Scaltriti M; Taylor BS; Chandarlapaty S; Baselga J; Hyman DM
Clin Cancer Res; 2020 Aug; 26(15):3947-3957. PubMed ID: 32312891
[TBL] [Abstract][Full Text] [Related]
2. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial.
Howell SJ; Casbard A; Carucci M; Ingarfield K; Butler R; Morgan S; Meissner M; Bale C; Bezecny P; Moon S; Twelves C; Venkitaraman R; Waters S; de Bruin EC; Schiavon G; Foxley A; Jones RH
Lancet Oncol; 2022 Jul; 23(7):851-864. PubMed ID: 35671774
[TBL] [Abstract][Full Text] [Related]
3. BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population.
Turner NC; Alarcón E; Armstrong AC; Philco M; López Chuken YA; Sablin MP; Tamura K; Gómez Villanueva A; Pérez-Fidalgo JA; Cheung SYA; Corcoran C; Cullberg M; Davies BR; de Bruin EC; Foxley A; Lindemann JPO; Maudsley R; Moschetta M; Outhwaite E; Pass M; Rugman P; Schiavon G; Oliveira M
Ann Oncol; 2019 May; 30(5):774-780. PubMed ID: 30860570
[TBL] [Abstract][Full Text] [Related]
4. Effect of Capivasertib in Patients With an AKT1 E17K-Mutated Tumor: NCI-MATCH Subprotocol EAY131-Y Nonrandomized Trial.
Kalinsky K; Hong F; McCourt CK; Sachdev JC; Mitchell EP; Zwiebel JA; Doyle LA; McShane LM; Li S; Gray RJ; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Conley BA; O'Dwyer PJ; Harris LN; Arteaga CL; Chen AP; Flaherty KT
JAMA Oncol; 2021 Feb; 7(2):271-278. PubMed ID: 33377972
[TBL] [Abstract][Full Text] [Related]
5. Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive breast cancer (FAKTION): a multicentre, randomised, controlled, phase 2 trial.
Jones RH; Casbard A; Carucci M; Cox C; Butler R; Alchami F; Madden TA; Bale C; Bezecny P; Joffe J; Moon S; Twelves C; Venkitaraman R; Waters S; Foxley A; Howell SJ
Lancet Oncol; 2020 Mar; 21(3):345-357. PubMed ID: 32035020
[TBL] [Abstract][Full Text] [Related]
6. AKT Inhibition in Solid Tumors With AKT1 Mutations.
Hyman DM; Smyth LM; Donoghue MTA; Westin SN; Bedard PL; Dean EJ; Bando H; El-Khoueiry AB; Pérez-Fidalgo JA; Mita A; Schellens JHM; Chang MT; Reichel JB; Bouvier N; Selcuklu SD; Soumerai TE; Torrisi J; Erinjeri JP; Ambrose H; Barrett JC; Dougherty B; Foxley A; Lindemann JPO; McEwen R; Pass M; Schiavon G; Berger MF; Chandarlapaty S; Solit DB; Banerji U; Baselga J; Taylor BS
J Clin Oncol; 2017 Jul; 35(20):2251-2259. PubMed ID: 28489509
[TBL] [Abstract][Full Text] [Related]
7. Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver A; Palafox M; Monserrat L; Brasó-Maristany F; Òdena A; Sánchez-Guixé M; Ibrahim YH; Villacampa G; Grueso J; Parés M; Guzmán M; Rodríguez O; Bruna A; Hirst CS; Barnicle A; de Bruin EC; Reddy A; Schiavon G; Arribas J; Mills GB; Caldas C; Dienstmann R; Prat A; Nuciforo P; Razavi P; Scaltriti M; Turner NC; Saura C; Davies BR; Oliveira M; Serra V
Clin Cancer Res; 2020 Jul; 26(14):3720-3731. PubMed ID: 32220884
[TBL] [Abstract][Full Text] [Related]
8. "The emerging role of capivasertib in breast cancer".
Andrikopoulou A; Chatzinikolaou S; Panourgias E; Kaparelou M; Liontos M; Dimopoulos MA; Zagouri F
Breast; 2022 Jun; 63():157-167. PubMed ID: 35398754
[TBL] [Abstract][Full Text] [Related]
9. Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial.
Schmid P; Abraham J; Chan S; Wheatley D; Brunt AM; Nemsadze G; Baird RD; Park YH; Hall PS; Perren T; Stein RC; Mangel L; Ferrero JM; Phillips M; Conibear J; Cortes J; Foxley A; de Bruin EC; McEwen R; Stetson D; Dougherty B; Sarker SJ; Prendergast A; McLaughlin-Callan M; Burgess M; Lawrence C; Cartwright H; Mousa K; Turner NC
J Clin Oncol; 2020 Feb; 38(5):423-433. PubMed ID: 31841354
[TBL] [Abstract][Full Text] [Related]
10. Circulating tumour DNA analysis to direct therapy in advanced breast cancer (plasmaMATCH): a multicentre, multicohort, phase 2a, platform trial.
Turner NC; Kingston B; Kilburn LS; Kernaghan S; Wardley AM; Macpherson IR; Baird RD; Roylance R; Stephens P; Oikonomidou O; Braybrooke JP; Tuthill M; Abraham J; Winter MC; Bye H; Hubank M; Gevensleben H; Cutts R; Snowdon C; Rea D; Cameron D; Shaaban A; Randle K; Martin S; Wilkinson K; Moretti L; Bliss JM; Ring A
Lancet Oncol; 2020 Oct; 21(10):1296-1308. PubMed ID: 32919527
[TBL] [Abstract][Full Text] [Related]
11. Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
Turner NC; Oliveira M; Howell SJ; Dalenc F; Cortes J; Gomez Moreno HL; Hu X; Jhaveri K; Krivorotko P; Loibl S; Morales Murillo S; Okera M; Park YH; Sohn J; Toi M; Tokunaga E; Yousef S; Zhukova L; de Bruin EC; Grinsted L; Schiavon G; Foxley A; Rugo HS;
N Engl J Med; 2023 Jun; 388(22):2058-2070. PubMed ID: 37256976
[TBL] [Abstract][Full Text] [Related]
12. Alpelisib Plus Fulvestrant in PIK3CA-Altered and PIK3CA-Wild-Type Estrogen Receptor-Positive Advanced Breast Cancer: A Phase 1b Clinical Trial.
Juric D; Janku F; Rodón J; Burris HA; Mayer IA; Schuler M; Seggewiss-Bernhardt R; Gil-Martin M; Middleton MR; Baselga J; Bootle D; Demanse D; Blumenstein L; Schumacher K; Huang A; Quadt C; Rugo HS
JAMA Oncol; 2019 Feb; 5(2):e184475. PubMed ID: 30543347
[TBL] [Abstract][Full Text] [Related]
13. Selective AKT kinase inhibitor capivasertib in combination with fulvestrant in PTEN-mutant ER-positive metastatic breast cancer.
Smyth LM; Batist G; Meric-Bernstam F; Kabos P; Spanggaard I; Lluch A; Jhaveri K; Varga A; Wong A; Schram AM; Ambrose H; Carr TH; de Bruin EC; Salinas-Souza C; Foxley A; Hauser J; Lindemann JPO; Maudsley R; McEwen R; Moschetta M; Nikolaou M; Schiavon G; Razavi P; Banerji U; Baselga J; Hyman DM; Chandarlapaty S
NPJ Breast Cancer; 2021 Apr; 7(1):44. PubMed ID: 33863913
[TBL] [Abstract][Full Text] [Related]
14. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
15. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
[TBL] [Abstract][Full Text] [Related]
16. Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.
Jhaveri K; Eli LD; Wildiers H; Hurvitz SA; Guerrero-Zotano A; Unni N; Brufsky A; Park H; Waisman J; Yang ES; Spanggaard I; Reid S; Burkard ME; Vinayak S; Prat A; Arnedos M; Bidard FC; Loi S; Crown J; Bhave M; Piha-Paul SA; Suga JM; Chia S; Saura C; Garcia-Saenz JÁ; Gambardella V; de Miguel MJ; Gal-Yam EN; Rapael A; Stemmer SM; Ma C; Hanker AB; Ye D; Goldman JW; Bose R; Peterson L; Bell JSK; Frazier A; DiPrimeo D; Wong A; Arteaga CL; Solit DB
Ann Oncol; 2023 Oct; 34(10):885-898. PubMed ID: 37597578
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial to evaluate the addition of alisertib to fulvestrant in women with endocrine-resistant, ER+ metastatic breast cancer.
Haddad TC; D'Assoro A; Suman V; Opyrchal M; Peethambaram P; Liu MC; Goetz MP; Ingle JN
Breast Cancer Res Treat; 2018 Apr; 168(3):639-647. PubMed ID: 29289986
[TBL] [Abstract][Full Text] [Related]
18. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study.
Gianni L; Bisagni G; Colleoni M; Del Mastro L; Zamagni C; Mansutti M; Zambetti M; Frassoldati A; De Fato R; Valagussa P; Viale G
Lancet Oncol; 2018 Feb; 19(2):249-256. PubMed ID: 29326029
[TBL] [Abstract][Full Text] [Related]
19. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomised, open-label, phase 2 trial.
Tolaney SM; Wardley AM; Zambelli S; Hilton JF; Troso-Sandoval TA; Ricci F; Im SA; Kim SB; Johnston SR; Chan A; Goel S; Catron K; Chapman SC; Price GL; Yang Z; Gainford MC; André F
Lancet Oncol; 2020 Jun; 21(6):763-775. PubMed ID: 32353342
[TBL] [Abstract][Full Text] [Related]
20. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
Kornblum N; Zhao F; Manola J; Klein P; Ramaswamy B; Brufsky A; Stella PJ; Burnette B; Telli M; Makower DF; Cheema P; Truica CI; Wolff AC; Soori GS; Haley B; Wassenaar TR; Goldstein LJ; Miller KD; Sparano JA
J Clin Oncol; 2018 Jun; 36(16):1556-1563. PubMed ID: 29664714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
